Clindamycin-Loaded Polyhydroxyalkanoate Nanoparticles for the Treatment of Methicillin-Resistant Staphylococcus Aureus-Infected Wounds

The study evaluates clindamycin-loaded polyhydroxyalkanoate nanoparticles (Cly-PHA NPs) as a treatment for methicillin-resistant Staphylococcus aureus (MRSA)-infected wounds. These nanoparticles, with a mean size of 216.2 nm and a drug loading of 6.76%, provide sustained clindamycin release over 2 days. In vitro and in vivo tests, including a mouse model, showed that Cly-PHA NPs significantly reduced bacterial viability by approximately 99.9% after 24 hours and enhanced wound healing compared to untreated controls. The study concludes that Cly-PHA NPs are a promising strategy for managing MRSA infections, offering effective antibacterial activity and promoting wound healing.